Phase 3 Readout
RYTM: Phase 3 Topline: Open-Label Extension Study of Setmelanotide in Patients With a Rare Genetic, Syndromic or Acquired D
June 24, 2026 · setmelanotide. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 24, 2026
- Company
- RHYTHM PHARMACEUTICALS, INC. (RYTM)
- Drug
- setmelanotide
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout
Phase 3 Topline: Open-Label Extension Study of Setmelanotide in Patients With a Rare Genetic, Syndromic or Acquired D
- Drug
- setmelanotide
- Indication
- Obesity Associated With Defects in Leptin-melanocortin Pathway